Skip to content
Acting Auditions – Lifestyle
Author:
NanoViricides
Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
May 11, 2026
NV-387 for The Treatment of Measles is Granted Orphan Drug Designation by The US FDA
May 4, 2026
Deadly Measles Cases Accentuate the Need for a Treatment – NV-387 is Here to Help Patients and Control Spread, Says NanoViricides
April 21, 2026
American Specialty Health Helps Millions of Eligible Members Prevent Injury with Expansion of Digital MSK Solution
April 15, 2026
National Digital MSK Leader Contributes to AHIP Partner-Initiative Leading to 11% Prior Authorization Reduction Amongst Payers
April 15, 2026
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides
April 7, 2026
Phase II Clinical Trial of Monkeypox Treatment by NV-387 to Commence Soon, Announces NanoViricides
April 1, 2026
American Specialty Health Coaching Program Earns Prestigious ‘Gold-Standard’ Endorsement
March 24, 2026
NanoViricides Presenting at NIBA’s 152nd Investment Conference in Fort Lauderdale, FL March 12, 2026 – Announces Manufacture of Phase II Clinical Product NV-387 Oral Gummies is Complete
March 11, 2026
←
Previous Page
1
2